The medical devices sector is typified by frequent change and innovation, in response to problems and issues faced by the healthcare industry. As a result, the sector has seen the emergence of several start-up medtech companies offering disruptive, cutting-edge solutions. Most of these are private companies, where data such as revenue is frequently not disclosed. National estimates for Pinnacle BioLabs sales in the US from 2016 to 2022, as well as year-on-year growth rates, can be viewed in GlobalData’s micro revenue report. Buy the report here.
Pinnacle BioLabs is a medical equipment company that manufactures and distributes point-of-care in vitro diagnostics devices for colorectal cancer. The company’s flagship product, Second Generation FIT test is a colon cancer test kit. The company offers the Second Generation FIT test in both over-the-counter form and as a CLIA waived test kit for use in physician office labs and hospitals. It also offers HomeLab PSA Micro device which tests total PSA and free PSA available in the blood. The company operates in the US and Nigeria. Pinnacle Bio is headquartered in Nashville, Tennessee, the US.
The key metrics of Pinnacle BioLabs related to marketed and pipeline products, ongoing clinical trials, active jobs and publications from 2022 are shown below:
As Pinnacle BioLabs is a privately held company, it is not required to disclose its financial information and there is no stock listed on an exchange. GlobalData has access to a proprietary data set containing invoice data from over 2,600 healthcare institutions in the US and is therefore able to use estimations of a company’s revenue and growth to value private companies such as Pinnacle BioLabs.
For a detailed understanding of the performance of Pinnacle BioLabs, buy the report here.